文献速递甲状腺疾病

良性甲状腺结节单次射频消融的中长期结局

Mid-to Long-term Outcomes After Single Radiofrequency Ablation of Nontoxic and Toxic Thyroid Nodules.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

中位随访3年以上显示,无毒性结节1、3、5年平均体积缩小79%、82%、86%,毒性结节缩小84%、88%、89%;无毒性结节再生长累积发生率17.3%(最长8年),毒性腺瘤甲亢复发累积发生率21.6%(7年)。单次RFA对83%无毒性结节和78%毒性腺瘤患者取得良好中长期结局,并发症可接受。

要点

  • 单次RFA后无毒性结节5年平均体积缩小86%,毒性结节缩小89%。
  • 无毒性结节再生长累积发生率17.3%(最长8年),毒性腺瘤甲亢复发累积发生率21.6%(7年)。
  • 单次RFA中长期结局良好者比例:无毒性结节83%,毒性腺瘤78%。

核心结论

  • 单次RFA治疗在83%无毒性结节和78%毒性腺瘤患者中取得良好的中长期结局,并发症发生率可接受。

研究设计与样本

  • 干预为局部麻醉下单极或双极射频消融。

主要发现

  • 无毒性结节中位基线体积10.1 mL(IQR 5.5-20),毒性结节7.2 mL(IQR 4.2-14.3)。
  • 实性或 predominantly 实性结节分别占81%和93%。
  • RFA后1、3、5年无毒性结节平均体积缩小79%、82%、86%,毒性结节缩小84%、88%、89%,此后保持稳定。
  • 54例(7.1%)无毒性结节患者出现再生长,最长8年累积发生率17.3%;15例(11.5%)毒性腺瘤患者甲亢复发,7年累积发生率21.6%。

关键数值与推荐

  • 无毒性结节再生长定义为RFA后结节体积较其最小体积增加≥50%。
  • 毒性腺瘤复发定义为甲亢复发。
  • 复发性甲亢患者中14例经低剂量放射性碘(11例)或第二次RFA(3例)后甲状腺功能正常。
  • 并发症:中度2.3%,重度0.3%。

临床怎么用

  • 单次RFA可作为良性甲状腺结节(无毒性及毒性腺瘤)的中长期治疗选择,但需告知患者再生长或甲亢复发的累积风险。
  • 对无毒性结节再生长或毒性腺瘤甲亢复发者,可考虑低剂量放射性碘或再次RFA。

局限性

  • 回顾性设计,仅部分患者(无毒性结节437例、毒性腺瘤58例)有≥3年随访数据。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the mid- to long-term recurrence rates after a single radiofrequency ablation (RFA) of benign thyroid adenomas. DESIGN: Retrospective review of data collected in a standardized prospective database. SETTING: Single-center thyroid clinic in Austria. PARTICIPANTS: Eight hundred ninety-six consecutive patients with either nontoxic nodules (n = 765) or toxic adenomas (n = 131). INTERVENTION: Mono- or bipolar RFA under local anesthesia. MAIN OUTCOME MEASURES: Recurrence defined as increase in nodule size after RFA treatment by ≥50% from its smallest volume (nontoxic adenomas) or relapse of hyperthyroidism (toxic adenomas). RESULTS: Follow-up periods of 3 years or more were available for 437 nontoxic and 58 toxic adenomas. The median baseline volume was 10.1 mL [interquartile range (IQR) 5.5-20] for nontoxic and 7.2 mL (IQR 4.2-14.3) for toxic nodules. Solid or predominantly solid nodules comprised 81% and 93%, respectively. After 1, 3, and 5 years, the average nodule volume decreased by 79%, 82%, and 86% for nontoxic and by 84%, 88%, and 89% for toxic nodules, remaining stable afterwards.In 54 patients (7.1%) with nontoxic nodules, regrowth occurred, with a cumulative incidence rate of 17.3% over a maximum of 8 years. Among 15 patients (11.5%) with toxic adenomas, recurrence of hyperthyroidism was observed over 7 years (21.6% cumulative incidence). Fourteen of these patients became euthyroid after low-dose radioiodine treatment (n = 11) or a second RFA (n = 3). Documented complications included 2.3% moderate and 0.3% severe cases. CONCLUSION: In our cohort, a single RFA treatment resulted in favorable mid- to long-term outcomes in 83% of nontoxic and 78% of toxic adenoma patients, with an acceptable complication rate.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dobnig H, Amrein K. Mid-to Long-term Outcomes After Single Radiofrequency Ablation of Nontoxic and Toxic Thyroid Nodules. J Clin Endocrinol Metab. 2026. PMID: 41192411. doi:10.1210/clinem/dgaf611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。